Advances in Therapy

, Volume 23, Issue 5, pp 672–679 | Cite as

Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma

  • Suleyman Alici
  • Serdar Ugras
  • Irfan Bayram
  • Mustafa Izmirli
Article

Abstract

Cyclooxygenase-2 (COX-2) is overexpressed in various types of human malignancies, including squamous cell carcinomas of the esophagus, but its clinicopathologic role in esophageal squamous cell carcinoma (ESCC) remains unclear. The aim of this study was to analyze expression of COX-2 in ESCC and to correlate this expression with clinicopathologic parameters and survival. From 1999 to 2003, endoscopic tissue samples from 110 patients with ESCC were collected for analysis. COX-2 expression was examined through immunohistochemical staining. Clinicopathologic data were analyzed to verify significance. COX-2 expression was detected in 50 of 110 ESCC specimens (45%). COX-2 expression was negative to weak in 73% (COX-2 low) and moderate to strong in 27% (COX-2 high) of tumors. Statistical differences between COX-2 high and COX-2 low were found according to status of the stage (stage IVM1a/IVM1b) (P=.001): cancer antigen (CA) 19-9 (normal/high) (P=.011), CA 12-5 (normal/high) (P=.011), and CA 15-3 (normal/high) (P=.035). Survival was significantly reduced among patients with high COX-2 expression (median overall survival, 3 mo) when compared with the COX-2 low group (median overall survival, 6 mo) (P=.0001). In the univariate analysis, age, body mass index, stage, COX-2, lactate dehydrogenase, CA 12-5, and CA 15-3 were significant factors for survival. With the use of COX regression analysis, only stage (P=.000), COX-2 (P=.000), lactate dehydrogenase (P=.023), and CA 15-3 (P=.002) were independent prognostic factors. Results showed that in patients with ESCC, COX-2 overexpression was significantly correlated with visceral metastases (IVM1b). COX-2 overexpression is an unfavorable prognostic factor in ESCC.

Keywords

esophageal squamous cell carcinoma prognostic factors COX-2 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nagamatsu M, Mori M, Kuano H, Sugimachi K, Akiyoshi T. Serial histologic investigation of squamous epithelial dysplasia associated with carcinoma of the esophagus.Cancer. 1992; 69: 1094–1098.PubMedCrossRefGoogle Scholar
  2. 2.
    Sarbia M, Verreet P, Bittinger F, et al. Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis.Cancer. 1997; 79: 1871–1878.PubMedCrossRefGoogle Scholar
  3. 3.
    Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CWJ. Aspirin use and risk of fatal cancer.Cancer Res. 1993; 53: 1322–1327.PubMedGoogle Scholar
  4. 4.
    Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications.Fundam Clin Pharmacol. 1996; 10: 1–17.PubMedCrossRefGoogle Scholar
  5. 5.
    William CS, Dubois RN. Prostaglandins endoperoxide synthase: why two isoforms?Am J Physiol. 1996; 270: 803–809.Google Scholar
  6. 6.
    Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.Cancer Res. 1999; 59: 991–994.PubMedGoogle Scholar
  7. 7.
    Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors.Cancer. 2000; 89: 2637–2645.PubMedCrossRefGoogle Scholar
  8. 8.
    Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma.Cancer Res. 1997; 57: 1276–1280.PubMedGoogle Scholar
  9. 9.
    Tucker ON, Dannenberg AJ, Yan EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.Cancer Res. 1999; 59: 987–990.PubMedGoogle Scholar
  10. 10.
    Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.Clin Cancer Res. 2001; 7: 861–867.PubMedGoogle Scholar
  11. 11.
    Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus.Gastroenterology. 2002; 122: 1800–1807.PubMedCrossRefGoogle Scholar
  12. 12.
    Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma.Cancer Res. 1999; 59: 198–204.PubMedGoogle Scholar
  13. 13.
    Biramijamel F, Allameh A, Mirbod P, Groene HJ, Koomagi R, Hollstein M. Unusual profile and high prevalence ofp53 mutations in esophageal squamous cell carcinoma from northern Iran.Cancer Res. 2001; 61: 3119–3123.Google Scholar
  14. 14.
    Kuo K-T, Chow K-C, Wu Y-C, et al. Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma.Ann Thorac Surg. 2003; 76: 909–914.PubMedCrossRefGoogle Scholar
  15. 15.
    Qiao L, Kozoni V, Tsioulias GJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cells and mouse colonocytes in vivo.Biochim Biophys Acta. 1995; 1258: 234–247.Google Scholar
  16. 16.
    Ferrandina G, Lauriola L, Distefano MG, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.J Clin Oncol. 2002; 20: 973–981.PubMedCrossRefGoogle Scholar
  17. 17.
    Yu HP, Xu SQ, Liu L, et al. Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus.Cancer Lett. 2003; 198: 193–201.PubMedCrossRefGoogle Scholar
  18. 18.
    Kawabe A, Shimada Y, Uchida S, et al. Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma andp53 expression.Oncology. 2002; 65: 46–54.CrossRefGoogle Scholar
  19. 19.
    Hida T, Yatabe Y, Achiva H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.Cancer Res. 1998; 58: 3761–3764.PubMedGoogle Scholar

Copyright information

© Health Communications Inc 2006

Authors and Affiliations

  • Suleyman Alici
    • 1
  • Serdar Ugras
    • 2
  • Irfan Bayram
    • 2
  • Mustafa Izmirli
    • 3
  1. 1.Oncology DepartmentBatikent-AnkaraTurkey
  2. 2.Pathology DepartmentMedical School ofYuzuncuYil UniversityVanTurkey
  3. 3.Radiation Oncology DepartmentMedical School ofYuzuncuYil UniversityVanTurkey

Personalised recommendations